• 1
    Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:251929.
  • 2
    American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: ACS, 2008.
  • 3
    Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 2003;90:3906.
  • 4
    Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975;42:1014.
  • 5
    Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994;170:9749.
  • 6
    Chi DS, Liao JB, Leon LF, Venkatraman ES, Hensley ML, Bhaskaran D, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;82:5327.
  • 7
    Eisenhauer EL, Abu-Rustum NR, Sonoda Y, Levine DA, Poynor EA, Aghajanian C, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC–IV epithelial ovarian cancer. Gynecol Oncol 2006;103:108390.
  • 8
    Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:1038.
  • 9
    Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:124859.
  • 10
    Pickel H. Spread of ovarian cancer. In: Surgical Gynecologic Oncology. Stuttgart: Thieme, 1993. pp. 4359.
  • 11
    Estes JM, Leath CA 3rd, Straughn JM Jr, Rocconi RP, Kirby TO, Huh WK, et al. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy. J Am Coll Surg 2006;203:52732.
  • 12
    Gillette-Cloven N, Burger RA, Monk BJ, McMeekin DS, Vasilev S, DiSaia PJ, et al. Bowel resection at the time of primary cytoreduction for epithelial ovarian cancer. J Am Coll Surg 2001;193:62632.
  • 13
    Jatoi A, Podratz KC, Gill P, Hartmann LC. Pathophysiology and palliation of inoperable bowel obstruction in patients with ovarian cancer. J Support Oncol 2004;2:32334. Discussion 334–7.
  • 14
    Akahira JI, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol 2001;81:398403.
  • 15
    Ng LW, Rubin SC, Hoskins WJ, Jones WB, Hakes TB, Markman M, et al. Aggressive chemosurgical debulking in patients with advanced ovarian cancer. Gynecol Oncol 1990;38:35863.
  • 16
    Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:113850.
  • 17
    Winter WE. 3rd, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:36217.
  • 18
    McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:16.
  • 19
    Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003;21:3194200.
  • 20
    Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:3443.
  • 21
    Carmichael JA, Shelley WE, Brown LB, Fraser RC, Kirk ME, Krepart GV, et al. A predictive index of cure versus no cure in advanced ovarian carcinoma patients – replacement of second-look laparotomy as a diagnostic test. Gynecol Oncol 1987;27:26981.
  • 22
    Pignata S, Ferrandina G, Scarfone G, Scollo P, Odicino F, Cormio G, et al. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study. Crit Rev Oncol Hematol 2009;71:23341.
  • 23
    Ota K, Ariyoshi Y, Urata A. Chemotherapy for metastatic lung cancer. Gan No Rinsho 1983;29:5337.
  • 24
    Porzio G, Ronzino G, Farina E, Aielli F, Ficorella C, Marchetti P. Cerebral metastasis from ovarian cancer treated with a multidisciplinary approach. Case report and review of literature. Eur J Gynaecol Oncol 2003;24:5634.
  • 25
    Gadducci A, Tana R, Teti G, Fanucchi A, Pasqualetti F, Cionini L, et al. Brain recurrences in patients with ovarian cancer: report of 12 cases and review of the literature. Anticancer Res 2007;27:44039.
  • 26
    Kolomainen DF, Larkin JM, Badran M, A’Hern RP, King DM, Fisher C, et al. Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence. J Clin Oncol 2002;20:9826.
  • 27
    Tiwari A, Kumar N, Bajpai R, Lal P. Bone metastasis from ovarian cancer. J Cancer Res Ther 2007;3:346.
  • 28
    Cain JM, Ellis GK, Collins C, Greer BE, Tamimi HK, Figge DC, et al. Bone marrow involvement in epithelial ovarian cancer by immunocytochemical assessment. Gynecol Oncol 1990;38:4425.
  • 29
    Krebs HB, Goplerud DR. Surgical management of bowel obstruction in advanced ovarian carcinoma. Obstet Gynecol 1983;61:32730.
  • 30
    Wittich G, Salomonowitz E, Szepesi T, Czembirek H, Fruehwald F. Small bowel double-contrast enema in stage III ovarian cancer. AJR Am J Roentgenol 1984;142:299304.
  • 31
    Yuhasz M, Laufer I, Sutton G, Herlinger H, Caroline DF. Radiography of the small bowel in patients with gynecologic malignancies. AJR Am J Roentgenol 1985;144:3037.
  • 32
    Jong P, Sturgeon J, Jamieson CG. Benefit of palliative surgery for bowel obstruction in advanced ovarian cancer. Can J Surg 1995;38:4547.
  • 33
    Pothuri B, Vaidya A, Aghajanian C, Venkatraman E, Barakat RR, Chi DS. Palliative surgery for bowel obstruction in recurrent ovarian cancer: an updated series. Gynecol Oncol 2003;89:30613.
  • 34
    Nahhas WA. Ovarian cancer. Current outlook on this deadly disease. Postgrad Med 1997;102:11220.
  • 35
    Salani R, Diaz-Montes T, Giuntoli RL, Bristow RE. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma. Ann Surg Oncol 2007;14:35527.